FDA approves the third anti-TB drug in more than 40 years after the compound showed significantly higher success rates in patients with multi drug-resistant and extensively drug-resistant TB.
According to the international medical humanitarian organisation
Médecins Sans Frontières (MSF), the World Health Organisation (WHO)
has failed to address the emergence of extensively drug-resistant
(XDR) tuberculosis.
The World Health Organisation (WHO) has revealed details of a
'super strain' of tuberculosis, which is not only resistant to
first choice treatment drugs, but also three or more of the six
classes of second-line drugs.
A new study has revealed the existence of new drug targets for
tuberculosis (TB) treatments, which could essentially dictate the
design of TB drugs of the future. The bacterium that causes TB
currently infects one person in three...
Oxford Immunotec makes available an in vitro diagnostic that
measures T-cells specific to Mycobacterium tuberculosis (MTB)
antigens diagnosing both latent and active TB infection in
immunocompromised humans - a significant problem...
The Foundation for Innovative New Diagnostics (FIND) and Eiken
Chemicals have announced a collaboration to develop a rapid and
simple test for the detection of active tuberculosis (TB), a
disease that has infected close to a third...
A new laboratory application for detecting tuberculosis, which cuts
waiting time from 24 hours to three minutes using a technique that
identifies TB antigens, has been made available by Proteome
Systems. The application is set to...
The Global Alliance for TB Drug Development has started testing a
promising tuberculosis drug in humans. This development represents
the first novel compound of a new class to be introduced for the
treatment of TB in more than 40...
A tuberculosis drug candidate, which has been described as the most
promising Tuberculosis (TB) drug in 40 years, may lead to a shorter
and more effective treatment.
Researchers have uncovered a novel treatment that could prove to be
effective against tuberculosis (TB), a disease that has made a
comeback due to the emergence of resistant strains of the offending
bacterium and the spread of AIDS.
A class of drug, which is currently used to fight respiratory tract
infections, has demonstrated pharmacological features and potential
antibacterial drug activity that may prove effective against
Tuberculosis, which is currently...
A novel approach to treating tuberculosis (TB), focusing on a
potential drug target in the cell walls of Mycobacterium
tuberculosis, the bacterium that causes TB, a disease that is
reappearing as new, multiresistant drug-strains.
With the incidence of drug resistant tuberculosis (TB) and dengue
fever rapidly accelerating worldwide, Novartis has announced the
opening of a non-profit initiative in drug discovery focussing on
advanced biomedical research for...
The European Commission has announced a collaborative tuberculosis
research initiative, underpinned by €32 million in funding for two
overlapping research projects aimed at developing an improved
vaccine for the disease. The news...